Current management of hepatocellular carcinoma

World J Gastroenterol. 2014 Aug 14;20(30):10223-37. doi: 10.3748/wjg.v20.i30.10223.

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and leading cause of death among patients with cirrhosis. Treatment guidelines are based according to the Barcelona Clinic Liver Cancer staging system. The choice among therapeutic options that include liver resection, liver transplantation, locoregional, and systemic treatments must be individualized for each patient. The aim of this paper is to review the outcomes that can be achieved in the treatment of HCC with the heterogeneous therapeutic options currently available in clinical practice.

Keywords: Barcelona Clinic Liver Cancer guidelines; Hepatocellular carcinoma; Management; Outcome; Therapeutic options.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / secondary
  • Carcinoma, Hepatocellular / therapy*
  • Hepatectomy* / adverse effects
  • Hepatectomy* / mortality
  • Hepatectomy* / standards
  • Humans
  • Liver Neoplasms / mortality
  • Liver Neoplasms / pathology
  • Liver Neoplasms / therapy*
  • Liver Transplantation* / adverse effects
  • Liver Transplantation* / mortality
  • Liver Transplantation* / standards
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Patient Selection
  • Practice Guidelines as Topic
  • Predictive Value of Tests
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents